Simulations Plus (NASDAQ:SLP) Updates FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY25 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $1.07-1.20 for the period, compared to the consensus estimate of $1.09. The company issued revenue guidance of $90-93 million, compared to the consensus revenue estimate of $90.40 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Up 7.8 %

Shares of SLP stock opened at $25.68 on Friday. Simulations Plus has a 12 month low of $23.01 and a 12 month high of $51.22. The company has a market cap of $515.96 million, a PE ratio of 64.20 and a beta of 0.89. The business’s 50 day moving average is $30.03 and its two-hundred day moving average is $30.29.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company had revenue of $22.43 million for the quarter, compared to the consensus estimate of $21.93 million. During the same period in the previous year, the business posted $0.20 EPS. The company’s revenue for the quarter was up 22.5% on a year-over-year basis. As a group, equities analysts expect that Simulations Plus will post 1.09 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on SLP. William Blair restated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp raised their price objective on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, StockNews.com upgraded Simulations Plus from a “sell” rating to a “hold” rating in a research note on Friday. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.40.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the transaction, the director now directly owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 19.40% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.